Clinical studies have used series of several to a dozen or so administrations, for example two or three times a week for four to six weeks
Semaglutide, the active ingredient in Ozempic, has FDA approval for adults 18 and older with type 2 diabetes or chronic weight management conditions
placebo, N=97), the adverse reactions reported regardless of investigator assessment of causality through Week 18 in 5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: upper respiratory tract infection (sitagliptin, 5.5%
Sfera A, Bullock K, Price A, Inderias L, Osorio C (2018) Ferrosenescence: the iron age of neurodegeneration
It should be noted that the Seattle protocol still has potential disadvantages, while it may decrease the risk of missed dysplasia, it still does not eliminate the issue completely
the role of interleukin-10